

**Clinical Outcomes in Concurrent Cohorts of Elexacaftor/Tezacaftor/Ivacaftor
(ELX/TEZ/IVA)-Treated Versus ELX/TEZ/IVA-Ineligible People with Cystic Fibrosis in the US
During COVID-19 – Supplementary Materials**

Christian A. Merlo¹, Hela Romdhani², Maral DerSarkissian², Aruna Muthukumar², Lisa J.
McGarry³, Yiyue Lou³, Kate Van Brunt³

¹Johns Hopkins University School of Medicine, Baltimore, MD, USA; ²Analysis Group, Los
Angeles, CA, USA; ³Vertex Pharmaceuticals, Boston, MA, USA

Corresponding Author:

Kate Van Brunt

Vertex Pharmaceuticals, 50 Northern Avenue, Boston, MA, USA

kate_vanbrunt@vrtx.com

ORCID: 0009-0007-9738-8302

SUPPLEMENTARY MATERIAL

Supplementary Table S1. Baseline Demographics and Clinical Characteristics Before SMR Weighting

	ELX/TEZ/IVA-Treated Cohort N = 13,414	ELX/TEZ/IVA Ineligible and Untreated Comparator Cohort Weighted N = 1,600	Standardized Difference
Age at index (years), Mean $\pm$ SD	26.73 $\pm$ 12.68	28.56 $\pm$ 15.73	-12.81%
Sex, (%)			
Female, (%)	46.89%	46.19%	1.41%
Male, (%)	53.11%	53.81%	
Race, (%)			
White	95.62%	79.19%	51.13%
Black/African American	3.21%	14.06%	-39.36%
Other ^a	2.73%	8.75%	-26.11%
Ethnicity, (%)			
Hispanic Origin	6.60%	19.25%	-38.41%
ppFEV₁ (baseline), ^b Mean $\pm$ SD	75.62 $\pm$ 23.81	76.97 $\pm$ 24.06	-5.62%
Change in ppFEV₁ (baseline), ^c Mean $\pm$ SD	-0.46 $\pm$ 6.65	-0.89 $\pm$ 7.73	6.01%
Number of PEx (baseline), ^d Mean $\pm$ SD	0.78 $\pm$ 1.34	0.68 $\pm$ 1.35	7.03%
CF genotype, (%)			N/A
Homozygous <i>F508del</i> [F/F]	53.20%	--	
Heterozygous <i>F508del</i> /Minimal Function [F/MF]	22.55%	--	
Heterozygous <i>F508del</i> /Residual Function [F/RF]	6.02%	--	
Heterozygous <i>F508del</i> /Other [F/Other]	8.93%	--	
Heterozygous <i>F508del</i> /Gating [F/Gating]	4.05%	--	
Heterozygous <i>F508del</i> / Unknown [F/Unknown]	2.55%	--	
Non- <i>F508del</i> ELX/TEZ/IVA-responsive	2.71%	--	
Minimal function/Minimal Function MF/MF	--	72.94%	
Other	--	27.06%	
Year and quarter of index date, n (%)			
2019			
Quarter 4	54.38%	52.75%	3.26%
2020			
Quarter 1	24.33%	27.81%	-7.95%
Quarter 2	5.62%	2.88%	13.65%
Quarter 3	4.23%	2.56%	9.20%
Quarter 4	3.66%	2.44%	7.12%

	ELX/TEZ/IVA-Treated Cohort	ELX/TEZ/IVA Ineligible and Untreated Comparator Cohort	Standardized Difference
	N = 13,414	Weighted N = 1,600	
2021			
Quarter 1	3.30%	4.63%	-6.82%
Quarter 2	2.32%	4.38%	-11.45%
Quarter 3	2.18%	2.56%	-2.54%

CF, cystic fibrosis; *ELX/TEZ/IVA*, elexacaftor/tezacaftor/ivacaftor; *PEX*, pulmonary exacerbation; *ppFEV₁*, percent predicted forced expiratory volume in one second; *SD*, standard deviation; *SMR*, standardized mortality ratio.

^aAmerican Indian or Alaska Native, Asian, Native Hawaiian or other Pacific Islander, and others not specified.

^bAverage of best available (i.e. highest value) in each quarter over the second year of the baseline period.

^cAverage of the best available *ppFEV₁* in each quarter over the second year of the baseline period minus the average of the best available *ppFEV₁* in each quarter over the first year of the baseline period.

^dDuring the second year of the baseline period.